British American Tobacco

British American Tobacco (BTI.US) declined steadily during regular trading, closing at $59.89, down 3.5% from the prior close, primarily dragged by sector contagion after Philip Morris cut its annual profit forecast, coupled with uncertainty around BAT's own AI-driven restructuring plan cutting 5,500 to 9,000 jobs. Despite Q4 revenue rising 7.43% YoY to $9.12 billion, net profit surging 336.69% to $2.15 billion, and EPS of $0.98, the stock fell below its 20-day ($61.27) and 60-day ($61.34) moving averages, standing 11.01% below the 52-week high of $67.30. Year-to-date, the stock is still up 5.91%. Intraday high of $61.86 was set in pre-market, but price weakened throughout the regular session. While Citi and BofA maintain Buy ratings, and the company repurchased £25.7 million of stock in the week to July 17, the near-term outlook remains cautious amid industry headwinds.

British American Tobacco surged 7.5% to close at $63.16 during regular trading, driven by cost-cutting plans including 5,500 job cuts and an AI-driven overhaul. The stock rose modestly in pre-market to $59.43 before accelerating to an intraday high of $63.31; it held steady in post-market at $63.16. In Q4 2025, revenue grew 7.43% YoY to $9.12 billion, net profit soared 336.69% to $2.15 billion, and EPS reached $0.9784. The stock now trades above its 20-day ($60.80) and 60-day ($60.92) moving averages, 6.15% below the 52-week high of $67.30, with a YTD gain of 11.69%. However, operating income dropped 3.26% YoY to $3.15 billion, signaling ongoing cost pressures.

British American Tobacco (BTI.US) rose 3.09% to $62.43 by 10:47 ET on Tuesday, driven by the announcement of a 'Fit2Win' restructuring plan to cut 9,000 jobs (about 19% of its global workforce) and aiming for annual cost savings of around £600 million by 2028, alongside share buyback and dividend commitments. Q4 2025 revenue grew 7.43% YoY to $9.12 billion, net profit surged 337% YoY to $2.15 billion, and EPS increased 338% YoY to $0.98. The stock remains 7.24% below its 52-week high of $67.30 but has crossed above its MA20 ($60.83) and MA60 ($60.53), with a YTD gain of 10.4%. Barclays maintained a Buy rating, though the near-term impact of the job cuts on revenue growth and the upcoming ex-dividend date may temper the advance.